Scholarlink

<p>Intratumor heterogeneity fundamentally challenges cancer treatment, as coexisting, molecularly distinct cell states with non-overlapping drug sensitivities can drive therapeutic resistance. We establish and validate a generalizable, network-based framework to systematically identify combination therapies targeting complementary tumor cell states. Applied to diffuse midline glioma (DMG)—a universally fatal pediatric malignancy—this approach identified master regulator protein dependencies in seven coexisting cell states, confirmed by pooled CRISPR–Cas9 assays. Perturbational transcriptional profiles for 372 clinically relevant drugs prioritized candidates predicted to invert state-specific master regulator activity. State-selective drug sensitivity was validated for eight out of nine (89%) drugs in vivo, including avapritinib, ruxolitinib and larotrectinib. Compared with monotherapy, co-administering drugs targeting complementary states significantly prolonged survival across virtually all combinations, with avapritinib plus ruxolitinib extending median survival nearly threefold versus vehicle and 1.5-fold versus avapritinib alone. These findings establish clinically actionable DMG combinations and a tumor-agnostic and mutation-agnostic framework for rational combination therapy design.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Ester Calvo Fernández,
  • Lorenzo Tomassoni,
  • Xu Zhang,
  • Junqiang Wang,
  • Aleksandar Obradovic,
  • Pasquale Laise,
  • Aaron T. Griffin,
  • Lukas Vlahos,
  • Hanna E. Minns,
  • Diana V. Morales,
  • Christian Simmons,
  • Matthew Gallitto,
  • Hong-Jian Wei,
  • Timothy J. Martins,
  • Pamela S. Becker,
  • John R. Crawford,
  • Theophilos Tzaridis,
  • Robert J. Wechsler-Reya,
  • James Garvin,
  • Robyn D. Gartrell,
  • Luca Szalontay,
  • Stergios Zacharoulis,
  • Cheng-Chia Wu,
  • Zhiguo Zhang,
  • Andrea Califano,
  • Jovana Pavisic

摘要

Intratumor heterogeneity fundamentally challenges cancer treatment, as coexisting, molecularly distinct cell states with non-overlapping drug sensitivities can drive therapeutic resistance. We establish and validate a generalizable, network-based framework to systematically identify combination therapies targeting complementary tumor cell states. Applied to diffuse midline glioma (DMG)—a universally fatal pediatric malignancy—this approach identified master regulator protein dependencies in seven coexisting cell states, confirmed by pooled CRISPR–Cas9 assays. Perturbational transcriptional profiles for 372 clinically relevant drugs prioritized candidates predicted to invert state-specific master regulator activity. State-selective drug sensitivity was validated for eight out of nine (89%) drugs in vivo, including avapritinib, ruxolitinib and larotrectinib. Compared with monotherapy, co-administering drugs targeting complementary states significantly prolonged survival across virtually all combinations, with avapritinib plus ruxolitinib extending median survival nearly threefold versus vehicle and 1.5-fold versus avapritinib alone. These findings establish clinically actionable DMG combinations and a tumor-agnostic and mutation-agnostic framework for rational combination therapy design.